test

Hari Anant Deshpande MD

Associate Professor of Medicine (Medical Oncology) and Assistant Professor of Surgery (Otolaryngology) and Assistant Clinical Professor of Nursing

Clinical Interests

Head and neck cancer; Genitourinary (GU) cancers; sarcomas; thyroid cancer.


Board Certifications

1998
Hematology, Internal Medicine, Board Certified
1995
Internal Medicine, Board Certified
1999
Medical Oncology, Board Certified

Patient Care Locations

 
hari_deshpandefaculty-clinicsfalsetruetrue6truefalsefalse
 

Clinical Trials

Conditions Study Title
Head and Neck Cancer, Larynx, and Lip, Oral Cavity and Pharynx A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer (ECOG E1305)
Head and Neck Cancer, Larynx, and Lip, Oral Cavity and Pharynx A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer (RTOG 0920) (CIRB)
Breast Cancer (ER, PR, and HER2 negative), Colorectal Cancer, Endometrial Cancer, Gastric Adenocarcinoma, Glioblastoma Multiforme, Head/ Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Prostate Cancer, Brain and Nervous System, Breast - Female, Breast - Male, Colon, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Female Genital, Ovary, Prostate, Rectum, and Stomach A Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Lung A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck (RTOG 1216)

More Clinical Trials...

Edit Profile